Sarcinelli, G. M.
Varinelli, L.
Ghislanzoni, S.
Padelli, F.
Lorenzini, D.
Vingiani, A.
Milione, M.
Guaglio, M.
Kusamura, S.
Deraco, M.
Pruneri, G.
Gariboldi, M.
Baratti, D.
Bongarzone, I.
Funding for this research was provided by:
Italian Ministry of Public Health (RF 2019-12370456, RF 2019-12370456, RF 2019-12370456, RF 2019-12370456, RF 2019-12370456, RF 2019-12370456, RF 2019-12370456)
Institutional grant (BRI 2021, BRI 2021, BRI 2021, BRI 2021, BRI 2021, BRI 2021)
European Union’s Horizon 2020 research and innovation programme (grant agreement No 101016923 (101.13039/100010661), grant agreement No 101016923 (101.13039/100010661), grant agreement No 101016923 (101.13039/100010661))
Article History
Received: 8 January 2024
Accepted: 19 June 2024
First Online: 28 June 2024
Declarations
:
: The study was conducted according to the Declaration of Helsinki and approved by the local Ethics Committee (Fondazione Istituto Nazionale dei Tumori, Milano prot. n. (134/13; I249/19). Written informed consent was obtained by all cancer patients enrolled in the study.
: The authors declare no competing interests.